X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (83) 83
index medicus (70) 70
hematology (66) 66
male (54) 54
female (52) 52
middle aged (49) 49
adult (45) 45
aged (43) 43
multiple myeloma (39) 39
life sciences (37) 37
oncology (30) 30
bortezomib (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
multiple myeloma - drug therapy (27) 27
treatment outcome (27) 27
survival (26) 26
multiple myeloma - mortality (25) 25
transplantation (24) 24
cancer (23) 23
stem-cell transplantation (23) 23
abridged index medicus (21) 21
prognosis (21) 21
lenalidomide (20) 20
multiple myeloma - therapy (20) 20
therapy (20) 20
aged, 80 and over (19) 19
disease-free survival (19) 19
dexamethasone - administration & dosage (18) 18
multiple myeloma - pathology (17) 17
follow-up studies (16) 16
recurrence (16) 16
immunology (15) 15
survival analysis (15) 15
[sdv.can]life sciences [q-bio]/cancer (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
dexamethasone (14) 14
thalidomide - administration & dosage (14) 14
[ sdv.can ] life sciences [q-bio]/cancer (12) 12
care and treatment (12) 12
hematopoietic stem cell transplantation (12) 12
myeloma (12) 12
survival rate (12) 12
thalidomide - analogs & derivatives (12) 12
transplantation, autologous (12) 12
chemotherapy (11) 11
hemic and lymphatic diseases (11) 11
transplantation, homologous (11) 11
medicine, general & internal (10) 10
stem cell transplantation (10) 10
thalidomide (10) 10
hematology, oncology and palliative medicine (9) 9
multiple myeloma - diagnosis (9) 9
multiple myeloma - genetics (9) 9
relapse (9) 9
stem cells (9) 9
adolescent (8) 8
cytogenetics (8) 8
multiple-myeloma (8) 8
patients (8) 8
retrospective studies (8) 8
[sdv]life sciences [q-bio] (7) 7
article (7) 7
autologous transplantation (7) 7
bone-marrow (7) 7
combined modality therapy (7) 7
diagnosis (7) 7
elderly-patients (7) 7
human health and pathology (7) 7
kaplan-meier estimate (7) 7
neoplasm staging (7) 7
prospective studies (7) 7
remission induction (7) 7
thalidomide - adverse effects (7) 7
abnormalities (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
blood (6) 6
bone marrow (6) 6
carfilzomib (6) 6
disease (6) 6
disease progression (6) 6
expression (6) 6
immune system diseases (6) 6
leukemia (6) 6
medical and health sciences (6) 6
medicin och hälsovetenskap (6) 6
melphalan (6) 6
mesh: humans (6) 6
patient outcomes (6) 6
risk (6) 6
staging system (6) 6
transplantation conditioning (6) 6
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (5) 5
age factors (5) 5
allogeneic stem cell transplantation (5) 5
analysis (5) 5
articles (5) 5
bone marrow transplantation (5) 5
boronic acids - administration & dosage (5) 5
child (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1055 - 1066
Journal Article
by Pertesi, M and Vallee, M and Wei, XM and Revuelta, MV and Galia, P and Demangel, D and Oliver, J and Foll, M and Chen, S and Perrial, E and Garderet, L and Corre, J and Leleu, X and Boyle, EM and Decaux, O and Rodon, P and Kolb, B and Slama, B and Mineur, P and Voog, E and Le Bris, C and Fontan, J and Maigre, M and Beaumont, M and Azais, I and Sobol, H and Vignon, M and Royer, B and Perrot, A and Fuzibet, JG and Dorvaux, V and Anglaret, B and Cony-Makhoul, P and Berthou, C and Desquesnes, F and Pegourie, B and Leyvraz, S and Mosser, L and Frenkiel, N and Augeul-Meunier, K and Leduc, I and Leyronnas, C and Voillat, L and Casassus, P and Mathiot, C and Cheron, N and Paubelle, E and Moreau, P and Bignon, YJ and Joly, B and Bourquard, P and Caillot, D and Naman, H and Rigaudeau, S and Marit, G and Macro, M and Lambrecht, I and Cliquennois, M and Vincent, L and Helias, P and Avet-Loiseau, H and Moreno, V and Reis, RM and Varkonyi, J and Kruszewski, M and Vangsted, AJ and Jurczyszyn, A and Zaucha, JM and Sainz, J and Krawczyk-Kulis, M and Watek, M and Pelosini, M and Iskierka-Jazdzewska, E and Grzasko, N and Martinez-Lopez, J and Jerez, A and Campa, D and Buda, G and Lesueur, F and Dudzinski, M and Garcia-Sanz, R and Nagler, A and Rymko, M and Jamroziak, K and Butrym, A and Canzian, F and Obazee, O and Nilsson, B and Klein, RJ and Lipkin, SM and McKay, JD and Dumontet, C and Division of Hematology and Transfusion Medicine and Lund University and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Hematogenomics and Lunds universitet and Avdelningen för hematologi och transfusionsmedicin
LEUKEMIA, ISSN 0887-6924, 09/2019, Volume 33, Issue 9, pp. 2324 - 2330
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 22, pp. 3664 - 3670
Journal Article
Blood, ISSN 0006-4971, 11/2006, Volume 108, Issue 10, pp. 3289 - 3294
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 20, pp. 2475 - 2482
Journal Article
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 8, pp. 3489 - 3495
Journal Article